https://www.statcounter.com/counter/counter.js
Web Analytics

Fresenius Kabi launches Phenylephrine Hydrochloride Injection, USP in US

German pharma company Fresenius Kabi has launched the Phenylephrine Hydrochloride Injection, USP in the US, which is an alpha-1 adrenergic receptor agonist indicated for raising blood pressure in adults with clinically important hypotension caused mainly from vasodilation, in such settings as anesthesia or septic shock.

Fresenius Kabi Phenylephrine Hydrochloride Injection, USP has been rolled out as a 1 mL single-dose vial and as 5 mL and 10 mL pharmacy bulk packages. Fresenius Kabi says that all the Phenylephrine presentations supplied by it are free from preservatives.

John Ducker – president and CEO of Fresenius Kabi USA said: “Fresenius Kabi is pleased to expand our anesthesia and analgesia portfolio with these three presentations of Phenylephrine Hydrochloride Injection.

“Generic alternatives like these play a vital role in patient care and support efforts to make medicines more affordable and accessible.”

Fresenius Kabi Phenylephrine Hydrochloride Injection, USP

Fresenius Kabi Phenylephrine Hydrochloride Injection, USP. Photo courtesy of Business Wire.

Fresenius Kabi is a global health care company which has specialization in medicines and technologies for infusion, transfusion and also clinical nutrition. The German pharma company is a developer, manufacturer and provider of injected and infused medicines in the US with particular expertise in producing generic alternatives to brand-name drugs.

For more pharma industry news, keep following Pharma News Daily.

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *